27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Novo Nordisk A/S (NYSE:NVO) will roll out its obesity treatment, Wegovy (semaglutide), in Europe in 2023 to ensure it has enough supply.
- Following the launch in the U.S. in mid-2021, Wegovy faced a significant bottleneck. Catalent Inc (NYSE:CTLT) received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind the supply shortage for Wegovy.
- Bloomberg reported that the pharma company had plans to launch Wegovy in the summer of this year in the U.K., with the rest of Europe by the end of 2022.
- In March this year, Novo more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug.
- Novo Nordisk aims to generate annual obesity drug sales of more than DKK25 billion by 2025.
- Wegovy has enjoyed as it became the first slimming prescription medicine in seven years. In the U.K. alone, the cost of obesity is estimated at £9.7 billion ($11.9 billion) by 2050, Novo Nordisk estimates.
- The company had a breakthrough with Wegovy, released in the U.S. in June 2021, and helped achieve a weight loss of 17% on average over almost two years.
- In November, Novo Nordisk announced its plans to invest DKK 5.4 billion to expand its facilities in Bagsvaerd, Denmark.
- Price Action: NVO shares are down 0.27% at $129.46 during the premarket session on the last check Tuesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!